AHA Coding Clinic® for HCPCS - 2020 Quarter 2; For Your Information
New HCPCS codes and dosage descriptors for certain drugs and biologicals effective April 1, 2020
The following new HCPCS codes have been created for reporting drugs and biologicals in the Ambulatory Surgery Center (ASC) setting: HCPCS Level II Code Long Descriptor Effective Date C9053 Injection, crizanlizumab-tmca, 1 mg April 1, 2020 C9056 Injection, givosiran, 0.5 mg April 1, 2020 C9057 Injection, cetirizine hydrochloride, 1 mg April 1, 2020 C9058 Injection, pegfilgrastim-bmez, biosimilar, (Ziextenzo) 0.5 mg April 1, 2020 ...
Subscribe or sign in to view the full article.
Article Overview
This brief article covers newly created HCPCS Level II codes for reporting certain drugs and biologicals in the Ambulatory Surgery Center setting, along with their effective date. It is intended for coding, billing, and reimbursement professionals who track quarterly HCPCS updates and need to stay current with payer reporting requirements.
Why This Topic Matters
Keeping track of HCPCS code updates is important for accurate claims reporting, charge capture, and compliance in outpatient facility settings.
What You Will Learn
- Which HCPCS Level II reporting updates are effective on April 1, 2020.
- Which types of drugs and biologicals are included in the update.
- How the article is organized around ASC-related code announcements.
- The scope of the article as a quarterly HCPCS update notice.
Who Should Read This
- Medical coders
- Billing specialists
- Charge capture staff
- Revenue cycle professionals
- ASC administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com